Hologic and Siemens Healthineers have sued each other in the U.S. District Court for the District of Delaware, each claiming the other’s breast tomosynthesis systems infringe its patents on technology.
Hologic filed its complaint November 16. It alleges that Siemens’ Mammomat B.brilliant digital mammography and breast tomosynthesis systems infringe five Hologic patents issued between 2013 and 2018. According to the complaint, the patents cover technology that moves the focal spot in the opposite direction to the x-ray tube during tomosynthesis exposures to reduce blur, as well as related control of the collimator.
Hologic wants a permanent injunction barring Siemens from making, using, selling, or importing the systems in the U.S. It is also seeking damages, a jury trial, and a finding of willful infringement, which would allow the court to triple the damages.
The complaint cites a June 10 ruling by the Düsseldorf Local Division of the Unified Patent Court (UPC). That ruling found Mammomat B.brilliant infringes the European counterpart of one of the patents and rejected Siemens’ challenge to the patent’s validity. Hologic acknowledged that the U.S. claims must be decided independently under U.S. law. However, it said the UPC proceeding “is relevant to the parties’ history and to Siemens’ knowledge of Hologic’s focal-spot-control technology.”
Three days earlier, on November 13, Siemens Medical Solutions USA, filed its own suit against Hologic. It alleges that Hologic’s Envision Mammography platform infringes its U.S. Patent No. 8,284,894. The patent was issued in 2012 and originally assigned to Philips. According to the complaint, Siemens Healthineers acquired it in July 2026 and transferred it to its U.S. unit in October.
The patent covers acquiring tomosynthesis projection images while the x-ray tube rotates continuously and the electron-beam focal spot moves across the anode in the opposite direction, offsetting the tube’s travel. Siemens said in the complaint that the conventional approach, in which the tube stops for each projection, lengthens total acquisition time.
Siemens alleges direct, induced, and contributory infringement. It claims the infringement is willful based partly on an August 13, 2026, email to Hologic that identified the patent. It is also seeking a permanent injunction, damages, and a jury trial.


















